MediWound (NASDAQ: MDWD) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.


This table compares MediWound and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MediWound -752.78% -326.32% -48.65%
Syndax Pharmaceuticals -4,294.59% -58.23% -45.65%

Insider & Institutional Ownership

23.5% of MediWound shares are held by institutional investors. Comparatively, 70.7% of Syndax Pharmaceuticals shares are held by institutional investors. 24.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MediWound and Syndax Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
MediWound $2.17 million 63.74 -$16.18 million ($0.75) -8.40
Syndax Pharmaceuticals $1.22 million 210.72 -$53.19 million ($2.84) -4.07

MediWound has higher revenue and earnings than Syndax Pharmaceuticals. MediWound is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MediWound has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 4.75, meaning that its share price is 375% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for MediWound and Syndax Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediWound 0 0 4 0 3.00
Syndax Pharmaceuticals 0 0 10 0 3.00

MediWound presently has a consensus price target of $10.33, indicating a potential upside of 64.02%. Syndax Pharmaceuticals has a consensus price target of $24.88, indicating a potential upside of 115.00%. Given Syndax Pharmaceuticals’ higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than MediWound.


Syndax Pharmaceuticals beats MediWound on 8 of the 12 factors compared between the two stocks.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company‚Äôs product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.